Previous 10 | Next 10 |
Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, and Eleven Therapeutics, a company leading the AI revolution in nucleic acid therapies, today announced that they have ...
Twist Bioscience Corporation (TWST) Q1 2022 Earnings Conference Call February 4, 2022 8:00 AM ET Company Participants Angela Bitting – Senior Vice President-Corporate Affairs and Chief ESG Officer Emily Leproust – Chief Executive Officer and Co-Founder Jim Thorburn – Chie...
Although Twist Biosciences (TWST -2.2%) earlier today raised its expected revenue range for FY 2022, shares are not responding. For FY 2022, revenue is now expected to be in the range of $189 million to $198 million vs. $180.3M consensus. In its FQ1 22 results, Twist reported that orders incr...
Gainers: IRadimed IRMD +8%. Meridian Bioscience VIVO +8%. Biofrontera (NASDAQ:BFRI) +6%. Inspira Technologies Oxy (NASDAQ:IINN) +6%. Taysha Gene Therapies (NASDAQ:TSHA) +5%. Losers: Lannett Company (NYSE:LCI) -24%. Vanda Pharmaceuticals (NASDAQ:VNDA) -22%. E...
Twist Bioscience press release (NASDAQ:TWST): Q1 GAAP EPS of -$0.91. Revenue of $42M (+48.9% Y/Y). Orders Increased 48% to $49.6M For the full fiscal year 2022: Revenue is now expected to be in the range of $189 million to $198 million vs. $180.3M consensus. Gross margin is expected to be bet...
-- Record Revenues of $42M; Increase of 49% over $28.2M in Fiscal 2021 -- -- Orders Increased 48% to $49.6M -- -- Increased Revenue Guidance for Fiscal 2022 -- Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of hi...
Twist Bioscience (NASDAQ:TWST) is scheduled to announce Q1 earnings results on Friday, February 4th, before market open. The consensus EPS Estimate is -$1.06 (-47.2% Y/Y) and the consensus Revenue Estimate is $38.22M (+35.5% Y/Y). Over the last 1 year, TWST has beaten EPS estimates 75% of the...
Twist Bioscience (NASDAQ:TWST) and Abcam (NASDAQ:ABCM) have announced a licensing agreement under which Abcam will use a proprietary Twist VHH phage library for antibody discovery, development and commercialization for diagnostic and research applications. Under the terms of the agreement, Tw...
Abcam to license in VHH phage library (1) from Twist, complementing in-house recombinant antibody capabilities Abcam to develop and commercialize antibodies for diagnostic and research use, with Twist retaining rights for therapeutic applications Reinforces Abcam...
Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today released its inaugural environmental social and governance (ESG) report highlighting Twist’s approach to susta...
News, Short Squeeze, Breakout and More Instantly...
Twist Bioscience Corporation Company Name:
TWST Stock Symbol:
NASDAQ Market:
Twist Bioscience Corporation Website:
Pure Biologics’ exploratory Phase 0 study to evaluate pharmacodynamic activity of PBA-0405 in solid tumors Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today a...
Company to host conference call at 8:00 AM ET Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that it will issue its financial results for the fiscal 2024 th...
Express Genes enable faster turnaround times Twist Express Antibodies, CHO starting at 13 business days Twist Express Antibodies, HEK293 starting at 10 business days Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of ...